Objectives: The aim of this study is to modify and validate a novel screening tool to determine the necessity of bone scans in Chinese PCa patients at the time of diagnosis. Methods: Five-hundred-and-one patients diagnosed with PCa between 2010 and 2013 at Zhongshan Hospital, Fudan University, were included in the study. All received bone scans using technetium 99m methylene diphosphonate (99mTc-​MDP) at the initial staging. Age, prostate-specific antigen (PSA) and alkaline phosphatase (ALP) at diagnosis, disease stage, and biopsy Gleason score were collected from all patients. Multivariate logistic regression analysis and discrimination analysis were performed. A validation analysis of this screening tool was performed by Shanghai Cancer Center, Fudan University. Results: Among the 501 patients, 84 (16.7%) of them had BM. The area under the ROC curve was 0.9006 (95% CI, 0.87-0.93). The sensitivity of the cut-off point was 94.1%, and the specificity was 58.3%. The validation analysis demonstrated an area under the ROC curve of 0.846 (95% CI, 0.805-0.887). Conclusions: Study results demonstrated that a baseline bone scan can be safely omitted for cT1-T3 PCa patients who have a PSA ≤39 ng/ml and an ALP ≤88 IU/l. This novel screening tool may help determine the necessity of including a bone scan at the time of initial diagnosis of PCa.

Keywords:
Alkaline phosphatase, Bone metastasis, Bone scan, Diagnosis, Prostate cancer
1.
Ming LI, Si-wei Z, Jian-hui MA, Wan-qing C, Yan-qun NA, Si-wei Z, et al: A comparative study on incidence trends of prostate cancer in part of cities and counties in China. Chin J Urol 2009;30:368-370.
2.
Ding-wei YE, Chang-ling LI: Epidemiological trends of prostate cancer: retrospect and prospect. China Oncology 2007;17:177-180.
3.
Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al: International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-1092.
4.
Oefelein MG, Ricchiuti V, Conrad W, Resnick MI: Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002;168:1005-1007.
5.
Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-176.
6.
Scosyrev E, Wu G, Mohile S, Messing EM: Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer 2012;118:5768-5776.
7.
McArthur C, McLaughlin G, Meddings RN: Changing the referral criteria for bone scan in newly diagnosed prostate cancer patients. Br J Radiol 2012;85:390-394.
8.
Tanaka N, Fujimoto K, Shinkai T, Nakai Y, Kuwada M, Anai S, et al: Bone scan can be spared in asymptomatic prostate cancer patients with PSA of <=20 ng/ml and Gleason score of <=6 at the initial stage of diagnosis. Jpn J Clin Oncol 2011;41:1209-1213.
9.
Wang Y, Guo J, Xu L, Zhao N, Xu Z, Wang H, et al: Should bone scan be performed in Chinese prostate cancer patients at the time of diagnosis? Urol Int 2013;91:160-164.
10.
Briganti A, Passoni N, Ferrari M, Capitanio U, Suardi N, Gallina A, et al: When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol 2010;57:551-558.
11.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al: EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124-137.
12.
Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, et al: Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:1081-1087.
13.
Zhou JQ, Zhu Y, Yao XD, Zhang SL, Dai B, Zhang HL, et al: [Necessity analysis of bone scan in patients with newly diagnosed prostate cancer]. Zhonghua Yi Xue Za Zhi 2013;93:248-251.
14.
Zhou JQ, Zhu Y, Yao XD, Zhang SL, Dai B, Zhang HL, et al: [The building and validation of a model to predict the bone metastases of patients with newly diagnosed prostate cancer]. Zhonghua Wai Ke Za Zhi 2012;50:999-1002.
15.
Lorente JA, Valenzuela H, Morote J, Gelabert A: Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med 1999;26:625-632.
16.
Wymenga LF, Boomsma JH, Groenier K, Piers DA, Mensink HJ: Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int 2001;88:226-230.
17.
Wolff JM, Ittel TH, Borchers H, Boekels O, Jakse G: Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase. Anticancer Res 1999;19:2653-2655.
18.
Lorente JA, Morote J, Raventos C, Encabo G, Valenzuela H: Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 1996;155:1348-1351.
19.
Salminen E, Ala-Houhala M, Korpela J, Varpula M, Tiitinen SL, Halleen JM, et al: Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer. Acta Oncol 2005;44:742-747.
20.
Ozu C, Nakashima J, Horiguchi Y, Oya M, Ohigashi T, Murai M: Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Int J Urol 2008;15:419-422.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.